Cellectar Biosciences Inc  

(Public, NASDAQ:CLRB)   Watch this stock  
Find more results for Simon Pedder�
-0.11 (-4.38%)
Jan 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.38 - 2.51
52 week 1.76 - 9.20
Open 2.51
Vol / Avg. 59,667.00/23,150.00
Mkt cap 19.14M
P/E     -
Div/yield     -
EPS -3.23
Shares 7.56M
Beta -0.32
Inst. own 51%
Jan 13, 2015
Cellectar Biosciences Inc at EBD Biotech Showcase
Nov 11, 2014
Q3 2014 Cellectar Biosciences Inc Earnings Call
Nov 11, 2014
Q3 2014 Cellectar Biosciences Inc Earnings Release
Nov 5, 2014
Cellectar Biosciences Inc at EBD Group BIO-Europe Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -18.77% -117.88%
Return on average equity -38.24% -181.86%
Employees 24 -
CDP Score - -


3301 Agriculture Dr
MADISON, WI 53716-4133
United States - Map
+1-617-2441616 (Phone)
+1-608-4418121 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc. is engaged in developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, its compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. The Company�s portfolio consists of PET imaging agents, optical imaging agents and therapeutic agents. The Company's I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. Its I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Its CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

Officers and directors

Stephen Anthony Hill M.D. Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Simon Pedder Ph.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Chad J. Kolean Chief Financial Officer, Vice President - Finance, Treasurer
Bio & Compensation  - Reuters
Jamey P. Weichert Ph.D. Chief Scientific Officer, Director
Age: 57
Bio & Compensation  - Reuters
Kathryn M. McNeil Vice President - Investor Relations, Public Relations and Corporate Communications
Bio & Compensation  - Reuters
Cameron Szakacs Ph.D. Vice President - Clinical Development
Age: 51
Bio & Compensation  - Reuters
J. Patrick Genn Vice President - Business Development
Age: 56
Bio & Compensation  - Reuters
Kevin Kozak M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Paul L. Berns Independent Director
Age: 47
Bio & Compensation  - Reuters
John P. Neis Independent Director
Age: 57
Bio & Compensation  - Reuters